Home › High Blood Pressure › NCT07090161
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
RecruitingPhase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
Who can join
Ages 18 to 65 · All sexes
Full eligibility criteria
Inclusion Criteria: * SiSBP \>/= 130 mmHg despite \>8 weeks treatment w/ 1 or more antihypertensive therapies Exclusion Criteria: * Confirmed Grade 3/severe hypertension (SiSBP \>/= 180 mmHg, SiDBP \>/= 120 mmHg), unstable cardiac disease, renal insufficiency
About the study
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants with Uncontrolled Hypertension
What is being tested
- iloperidone (drug)
- Placebo (drug)
Sponsor: Vanda Pharmaceuticals · Participants: 240 · Started: Sep 15, 2025
Contact the study team
- Vanda Pharmaceuticals, Inc. · Phone: 202-734-3400
Official record on ClinicalTrials.gov — NCT07090161
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.